TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03421639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analog (11.25mg Leuprolide acetate)
Description: 11.25 Leuprolide acetate only one administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and GnRH analog
Description: 1mg/day of Anastrazole for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase and GnRH analog (11.25mg Leuprolide acetate)
Description: Leuprolide acetate 11.25mg only one
Study: NCT01642433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 3x daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin medication, 3x daily dosing, up to 15mg/day
Study: NCT02832349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Actions
Description: Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
Study: NCT00652509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Dialogue to Educate and Activate (IDEA)
Description: IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Education (IE)
Description: IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
Study: NCT01696786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte cryopreservation
Description: Oocyte (egg) cryopreservation (freezing) to preserve fertility
Study: NCT03001622

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IFX-1
Description: chimeric, monoclonal antibody
Study: NCT03512197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
Study: NCT03627715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propagermanium
Description: Immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study: NCT02118350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mat Pilates Training
Description: Mat Pilates training performed two times at week for 16 weeks.
Study: NCT03512197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
Study: NCT04865692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFRT
Description: Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
Study: NCT03011437

Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
Study: NCT02624128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
Study: NCT02190721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tbo-filgrastim
Description: 5 μg/kg
Study: NCT04865692

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy
Description: knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
Study: NCT03557814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED appliance during mechanical debridement
Description: Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED appliance after mechanical debridement
Description: Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mechanical debridement alone
Description: Mechanical debridement by periodontal curets alone
Study: NCT04046263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucroferric Oxyhydroxide Chewable Tablet
Description: Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
Study: NCT04425811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiological taping
Description: The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kinesiological taping
Description: The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
Study: NCT01054313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Description: Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (Rapamycin)
Description: Starting dose 1 mg daily by mouth 1 time a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice a day with prostate cancer.
Study: NCT04663854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trehalose
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
Study: NCT03423147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate cloth
Description: applied to their abdomen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine gluconate cloth
Description: applied to their abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine gluconate vaginal scrub
Description: applied as a vaginal cleanse in the operating room prior to cesarean section
Study: NCT03879551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study: NCT03236571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
Study: NCT04933864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue and Photodynamic Therapy
Description: Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed.
Study: NCT00840034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets PO QD for up to 12 weeks
Study: NCT03605472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical ultrasound
Description: cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
Study: NCT03411902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate Sodium 150 MG
Description: Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
Study: NCT03909698

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
Study: NCT01072747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bovine heparin
Description: 5.000UI/mL bottle with 5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Porcine heparin
Description: 5000 USP Heparin Units / mL vial with 10 mL vial
Study: NCT04099537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized cognitive training
Description: Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
Study: NCT02336009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: total wrist arthroplasty, Trimed
Description: A new total wrist arthroplasty design. A pilot study.
Study: NCT00280696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use
Study: NCT00450515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Study: NCT00613613

Intervention type: DRUG
Intervention: fenofibrate
Description: Fenofibrate 145mg tablets once daily for 4 weeks

Intervention type: DRUG
Intervention: fenofibrate
Description: Fenofibrate 145mg tablets once daily for 4 weeks
Study: NCT00280696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg and 500 mg~* Route of Administration: Oral Use
Study: NCT02502695

Intervention type: OTHER
Intervention: VATS-associated best practices

Intervention type: OTHER
Intervention: VATS-associated best practices
Study: NCT00960973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Description: Menatetrenone 30 mg, 3 times a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01440582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction Therapy (Part A, 21-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Completed on day 1 of each cycle.
Study: NCT04865692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
Study: NCT03542162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healaflow
Description: For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
Study: NCT01151423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: * Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received caplacizumab up to 30 days after the last PE session.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received placebo up to 30 days after the last PE session.
Study: NCT03635736

Intervention type: OTHER
Intervention: multiple-spectral-sonography as acustocerebrography (ACG)
Description: After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.